23 MAY
Starts at
08:00 EDT

Le Meridien
Cambridge Boston
Le MERIDIEN

Proventa International's 8th Annual

BIOINFORMATICS

STRATEGY MEETING EAST COAST USA 2022

Accelerate Your Ability to Understand Methods for
Data Mining → Storing → Integrating and Analysing
Biological Data to Increase the Breadth of Drugs in R&D

Digitalisation · AI/ML · Data Mining · Data Analytics · Informatics · Deep Learning · Data Harmonisation · Data Integration · NLP · NGS · Genomics · RWE/RWD · F.A.I.R

Featuring Industry Leaders and Decision Makers

Panna Sharma
President, CEO
Lantern Pharma

Hongyue Dai
VP, Translational Bioinformatics
LifeMine Therapeutics

Priya Bhambi
Global Head of Portfolio & Transformation
Takeda

Robert Van Den Berg
Senior Director, Head Data Science & Computational Vaccinology
GSK

Artur Veloso
Head of Bioinformatics
Repare Therapeutics

David Sexton
Senior Director, VP, Digital Lab Systems
Harbinger Health

John Chan
Head, ShinrAI Center for Artificial Intelligence/ Machine Learning
Takeda

OUR SPONSORS

BIOVIA · CytoReason · PRECISION quartzbio · Dotmatics · Quantum · excelra · Benchling · CrucialLogics · varsome

Click here to find out what our clients think about our
STRATEGY MEETINGS!

Visit our website for future events →

proventainternational.com
UK: +44 (0)20 3314 0100 | **US:** +1 (617) 614 0377
info@proventainternational.com
Proventa International
@proventaintl
@proventainternational
PROVENTA INTERNATIONAL

Proventa International's Strategy Meetings are a completely unique experience.

BIOINFORMATICS
STRATEGY MEETING
EAST COAST USA 2022

23 MAY

Our Vision



To be a platform for creating life-saving therapies and to facilitate the creation of a completely patient centric pharmaceutical industry.

Our Mission



By encouraging key leaders and their companies to put the patient at the very heart beat of every innovation. Sharing valuable insights and strategies to assist in the discovery, development and commercialisation of life saving therapies.

Our Unique Meeting Format

ROUNDTABLE DISCUSSIONS

These interactive and informal discussion groups are the hallmark of the meeting. The brightest minds in the industry are brought together in 60-minute sessions that enable participants from all over the world to share ideas, challenges and lessons learned.

PERSONALISED AGENDA

Each delegate receives a personalised agenda with the roundtable discussions that you choose. You only attend sessions and meetings that fit your challenges and interests, ensuring your time spent is focused and well-utilised.

INNOVATIVE SOLUTIONS

The most effective and time efficient way to assess potential partners at a strategic level. Identify key solution providers that can take your business to the next level and we will help arrange private meetings so you can connect.

STRATEGIC NETWORKING

Strategic networking opportunities form a key benefit of the meeting. Our proven format for building and strengthening alliances to make lasting connections that benefit you.

Advancements in technologies have led to the ability to generate more data. Alongside computational power increase, bioinformatics aims to develop software tools that generate useful biological knowledge to accelerate the ability to understand methods for

Data Mining → Storing → Integrating and Analysing

biological data to increase the breadth of potential drugs in R&D pipelines.

Why this strategy meeting is a MUST ATTEND FOR YOU AND YOUR TEAM!

- Gain insights from novel approaches facilitating effective digital transformation within your organization from technology trends to enabling your workforce and instilling the appropriate culture for change
- Explore new analytical and visualization tools to make better predictions and informed decisions throughout preclinical and clinical stages
- Demonstrating effective implementation of new technologies such as AI/ML in drug discovery and development
- Unique one-day strategy meeting allows you to benchmark and network with the likes of computational scientists, data scientists, bioinformaticians and industry leaders to tackle pressing challenges covering the breadth of omics-driven approaches, translational medicine, AI/ML, and data
- Constructive roundtable discussions will address how different companies can incorporate AI/ML models into daily drug discovery processes
- Learn strategies to turn research problems into software problems
- Exchange with your peers to learn how others are generating and structuring the right data to speed-up drug development

SENIORITY OF ATTENDEES



- Director Level
- Department Head
- Scientist
- President / VP
- Other
- Team Lead
- Academia
- Bioinformatician
- Manager
- C-Level

Facilitator Faculty

John McCarthy
VP, Field Applications
BIOVIA, Dassault Systèmes

Kai Zhang
Director, Product Marketing
BIOVIA, Dassault Systèmes

Luke Fisher
Global Leader, Biosciences Industry Process Consultants
BIOVIA, Dassault Systèmes

David Crowley
Global Client Executive
BIOVIA, Dassault Systèmes

Matt Harvey
Solution Sales Consultant
BIOVIA, Dassault Systèmes

Mitchell Winfree
Sales Leader
BIOVIA, Dassault Systèmes

Prof. Shai Shen-Orr
Co-founder and Chief Scientist
CytoReason

Mike Waters
Vice President
QuartzBio, part of Precision for Medicine

Tim Sherbak
Product and Solutions Marketing
Quantum

Chandra Sekhar Pedamallu
Associate Vice President - Bioinformatics
Excelra

Garrick Myers
Head of Enterprise Customer Success
Benchling

Loren Perelman
Head of Enterprise Professional Services
Benchling

Nim Nadarajah
Partner, Advisory Services
CrucialLogics

Amol Joshi
Partner, Enterpise Solutions
CrucialLogics

Priya Bhambi
Global Head of Portfolio & Transformation
Takeda

Govinda Bhisetti
Principal Investigator and Head of Computational Chemistry
Biogen

John Chan
Head, ShinrAI Center for Artificial Intelligence/ Machine Learning
Takeda

Clément Chatelain
Head Human Genetics and Genomics, Precision Medicine & Computational Biology
Sanofi

Robert Van Den Berg
Senior Director, Head Data Science & Computational Vaccinology
GSK

Hongyue Dai
VP, Translational Bioinformatics
LifeMine Therapeutics

David Sexton
Senior Director, VP, Digital Lab Systems
Harbinger Health

Piero Ricchiuto
Associate Director Bioinformatics, Computational Biology & Biomarker Discovery
Alexion, AstraZeneca Rare Disease Unit

Panna Sharma
President & CEO
Lantern Pharma

Artur Veloso
Head of Bioinformatics
Repare Therapeutics

Gayle Wittenberg
VP Neuroscience Data Science and Digital Health
Janssen

Our Sponsors

BIOINFORMATICS
STRATEGY MEETING
EAST COAST USA 2022

23 MAY

Lead Sponsor

BIOVIA, a brand of Dassault Systèmes, provides a scientific collaborative environment for advanced biological, chemical and materials experiences that allows science-driven companies access, organize, analyze and share data in unprecedented ways throughout the product lifecycle in regulated and non-regulated environments. BIOVIA's sophisticated enterprise portfolio of Scientific Informatics, Molecular Modeling & Simulation, Data Science, Laboratory Informatics, Formulation Design, Life Sciences Quality & Compliance and Manufacturing Analytics helps drive innovation, increase productivity, improve quality and compliance, reduce costs and accelerate time to market. BIOVIA is committed to enhancing and speeding innovation, increasing productivity, improving quality and compliance, reducing costs and accelerating product development for pharma and biotech companies around the world."

VISIT WEBSITE

Thought Leader

CytoReason is a tech company developing a computational model of the human body. The company collects proprietary data from pharma companies and uses it to simulate human diseases – tissue by tissue, cell by cell. With CytoReason's massive database and AI-led platform, pharma and biotech companies identify new opportunities, shorten trial phases, reduce development costs, and increase the likelihood of drug approval. To date, five of the world's top ten pharma companies use CytoReason's technology.

VISIT WEBSITE

Co-host Sponsors

QuartzBio's technology-enabled solutions support hundreds of clinical trials, managing thousands of data sets. Our platform is engineered specifically for monitoring biomarker sample status, informed consent tracking, biomarker data management, data delivery, visualization, analytics, and reporting. By integrating sample data with clinical, PK, and biomarker data in a centralized data platform, we enable clinical and translational teams to generate scientific and operational insights, on-study and across trials. For more information, visit QuartzBio.com.

VISIT WEBSITE

Dotmatics delivers a ready-to-use platform to capture, register, share, collaborate, query, visualise and analyse all the information and knowledge generated in the modern, highly collaborative scientific industries. Dotmatics has significant expertise in scientific informatics, including database management for chemistry and biologics, electronic laboratory notebooks, chemical and biological registration, screening data management, SAR analysis, reporting, and visualisation. The enterprise solutions are flexible, scalable and configurable, providing effective scientific information management across entire organisations, from discovery research to development and early manufacturing.

VISIT WEBSITE

Quantum technology, software, and services provide the solutions that today's organisations need to make unstructured data smarter – so their data works for them and not the other way around. With over 40 years of innovation, Quantum's end-to-end platform is uniquely equipped to orchestrate, protect, and enrich data across its lifecycle, providing enhanced intelligence and actionable insights. Leading organisations in life sciences research, education, and enterprise IT trust Quantum to bring their data to life, because data makes life better, safer, and smarter.

VISIT WEBSITE

Excelra empowers innovation in life sciences across the value chain from discovery to market leveraging its globally leading data engineering and analytics solutions. We support our clients with data structuring, data management, and data analysis services. Our analytics services include bioinformatics, data science, and statistical analytics services. We help our clients generate value from data by providing insights for better and accelerated decision-making. Our experience in handling a variety of OMICs data both proprietary and public, to help deliver on a plethora of objectives such as Target ID, Patient stratification, Biomarker ID, Drug repositioning, and Indication Expansion help in accelerating early discovery, translation studies and help improve the efficiency of clinical trials and more targeted therapies reaching patients leading to better healthcare outcomes. It also gives Excelra an added advantage in being able to engineer Bio-IT Infrastructure solutions for the same audience. Over the past 18 years, Excelra has been the preferred data and analytics partner to over 160 global clients, including 16 of the top 20 large Pharma. . EXCELRA has a multi-skilled team that includes core biologists and R&D-IT engineers to seamlessly address all aspects of bioinformatics data analysis.

VISIT WEBSITE

Benchling centralizes, standardizes, and governs data at scale, improves collaboration, and provides insights—all on a trusted and open platform that's built to scale, maximize security, compliance, and connectivity. Built for complex science with a focus on biology, Benchling's R&D Cloud accelerates the full R&D lifecycle with an easy-to-use platform consisting of three software layers: data, collaboration, and insights. With better data quality, improved throughput, and faster adoption of scientific technologies, the world's most innovative biotech organizations and nearly half of the largest biopharma companies trust Benchling to power the development of breakthrough products and accelerate time to milestone and market.

VISIT WEBSITE

We are an advisory first company. Our goal is to not sell technology solutions. **CrucialLogics** drives business outcomes through the development of masterfully planned and meticulously executed IT strategies. We're in the business of helping CIOs and business leaders accomplish their goals from inception to implementation, producing solutions that enable our clients to enter new markets, transform IT investments, and transition smoothly to new technology systems.

VISIT WEBSITE

VarSome maintains, harmonizes, and integrates over 130 genomic databases and over 32 million publications to give you the most comprehensive variant interpretation engine there is. Cited in over 1700 peer-reviewed publications, VarSome's proprietary ACMG, AMP, and CNV classifiers apply industry standard variant interpretation guidelines to help you understand your variants. VarSome's network boasts over 400 000 users around the world, adding variant classifications and additional annotation. The VarSome Suite ensures that there is a version of VarSome that works around you, whether you need to Search, Analyze, Code or Find.

VISIT WEBSITE

Intimate format events where senior leadership discuss the biggest challenges facing the industry.

How it Works?

BIOINFORMATICS
STRATEGY MEETING
EAST COAST USA 2022

23 MAY

Real insights are shared in conversations, not lectures. That's why our unique **roundtable** format guarantees real learning and ensures you only attend discussions that deliver value to you.

Join as many as four roundtable discussions, each with up to 20 other subject experts, networking with top-level peers in an informal, relaxed and sociable environment.

Simply follow the steps below to select your roundtable discussions and we'll create your own personalised agenda for the day:

01

EXPLORE THE FULL AGENDA

Select which roundtable discussions you would like to join. Our sessions are divided among 6 themed tracks for easy selection - you can choose to join any session you like.

02

COMPLETE YOUR SCHEDULING FORM

Select your preferred roundtable discussion for each time slot. We will send this form out via email a few weeks before the event - be sure to get your first choice by completing the form quickly.

03

ENJOY YOUR PERSONALISED EXPERIENCE

Join your selected roundtable sessions on the day. We will give you your personalised agenda containing the time and room assignments of your chosen roundtable discussions so you won't miss it.

Agenda at a Glance

Bioinformatics Strategy Overview 23rd of May, 2022 – Cambridge, Boston - Le Meridien Hotel

TIME EDT	TRACK 1 DIGITAL TRANSFORMATION	TRACK 2 ANALYTICS & VISUALISATION	TRACK 3 ARTIFICIAL INTELLIGENCE / MACHINE LEARNING	TRACK 4 DATA MANAGEMENT / ARCHITECTURE	TRACK 5 OMICS-DRIVEN APPROACHES	TRACK 6 DATA INTEGRATION / BIG DATA
08:00 - 08:30	REGISTRATION AND WELCOME					
08:30 - 09:00	BIOVIA	OPENING KEYNOTE PRESENTATION/PANEL What are the limits to virtual 'crash testing' of novel therapies?			BIOVIA	
09:00 - 10:00	Enabling your workforce: Necessary steps to equip teams to digitally transform the organization	Networks and system biology for novel targets and biomarker identification in rare-diseases	Learnings from AI: Accelerating the Expansion of AI and Building Powerful AI Capabilities Internally		A discussion on integrating multi-omics and clinical data to streamline precision medicine	Building and Leveraging Big Data Assets to Drive Value End-to-End in the Pharmaceutical Pipeline
10:00 - 10:10	MORNING BREAK					
10:10 - 10:30	NETWORKING / 1-1 MEETINGS					
10:30 - 10:50	NETWORKING / 1-1 MEETINGS					
10:50 - 11:10	NETWORKING / 1-1 MEETINGS					
11:10 - 12:10 SOLUTION	Latest Trends and Innovations to Enable Digital Transformation of Biotech and Pharma R&D BENCHLING Benchling	Leveraging Data Analytics for the Lab and Beyond BIOVIA BIOVIA	The Case for Scientific Portfolio Management CYTOREASON CytoReason	Addressing Data Residency, Analysis, and Growth Challenges with a Hyperscaler Mentality QUANTUM Quantum	Turning Multi-omic Data Chaos into Translational Insights QUARTZ BIO quartzbio	
12:10 - 13:10	NETWORKING LUNCH					
13:10 - 13:40	CytoReason		KEYNOTE PRESENTATION Closing the Data-Insight Gap		CytoReason	
13:40 - 14:40 SOLUTION	Digital Transformation in BioPharma Today and in the Future BIOVIA BIOVIA		Applying AI and Machine Learning for Accelerated Drug Design BIOVIA BIOVIA	Sharing the Best Strategies to Secure Your Data with Microsoft Technologies CRUCIALLOGICS CrucialLogics	Integrating multi-tissue multi-omics data to gain insights into disease EXCELRA excelra	
14:40 - 14:50	AFTERNOON BREAK					
14:50 - 15:10	NETWORKING / 1-1 MEETINGS					
15:10 - 15:30	NETWORKING / 1-1 MEETINGS					
15:30 - 15:50	NETWORKING / 1-1 MEETINGS					
15:50 - 16:50	Transforming Drug Discovery Pipelines Through Innovative Leveraging of AI	Assessing the best visualization and analytical tools to assist in making better informed decisions	Furthering Organization-Wide Capabilities By Unlocking The Power of Scalable AI	Transforming biopharma R&D with Quantum Computing	Addressing the challenges associated with large scale omics data analysis	Addressing the challenge of integration, mining, and analysis of enterprise-wide or consortia-level datasets
16:50 - 17:20	PANEL DISCUSSION AI's Expansion in Pharma and Biotech World					
17:20 - 18:20	DRINKS & CANAPES RECEPTION					

Event Day



OPENING KEYNOTE PRESENTATION/PANEL

8:30 – 9:00 EDT

What are the limits to virtual 'crash testing' of novel therapies?

BIOVIA

Luke Fisher
Global Leader, Biosciences Industry Process Consultants
BIOVIA, Dassault Systèmes

ABOUT THE SPEAKER

Luke Fisher is the Global Leader for the Bioscience Industry Process Consultants at BIOVIA / Dassault Systèmes. His background brings more than twenty years of experience in scientific informatics solutions. Luke has domain knowledge across the scientific informatics industry including past leadership positions at BIOVIA / Dassault Systèmes, ACD/Labs, CDD, Perkin Elmer and Dotmatics. He have supported a broad range of industries including the world's leading pharmaceutical, biotech, agricultural, chemicals, academic and government labs. Luke brings experience in scientific software solutions from the smaller scale deployment of point solutions (like molecular modeling packages) to the larger enterprise scale of ELNs, scientific workflow technologies, data content, analysis and visualization. In his current role, Luke and his group supports all global customers of laser focused on growth within the Design to Cure and Generative Therapeutics Design initiatives. He has a Ph.D. in computational chemistry from the University of Wisconsin Milwaukee.

END OF OPENING KEYNOTE

KEYNOTE PRESENTATION

13:10 - 13:40 EDT

Closing the Data-Insight Gap

- **The volume of biological data is growing exponentially. But our analytic capabilities are growing linearly (at best), broadening the data-insight gap**
- **Computational disease models can help close the gap, by processing high throughput data, while mapping and comparing treatments, patient groups and disease mechanisms**

CYTOREASON

Prof. Shai Shen-Orr
Co-founder and Chief Scientist
CytoReason

ABOUT THE SPEAKER

Professor Shai Shen-Orr is the Co-founder and Chief Scientist of CytoReason, a technology company developing computational disease models. He serves as Associate Professor in the Faculty of Medicine at the Technion—where he directs the laboratory of Systems Immunology and Precision Medicine. In his research, Prof. Shen-Orr develops new analytical methodologies for grappling with the intricate complexities of the immune system, especially as they occur in advanced age, and for defining biomarkers to evaluate immune health. His work has been featured and cited in numerous top-tier journals and systems biology textbooks, and has laid the foundation for CytoReason's disease models. To date, six of the world's top ten pharma companies use CytoReason's technology to speed up drug discovery and dramatically cut the cost of developing new medicines.

END OF KEYNOTE

Event Day

PANEL DISCUSSION

16:50 - 17:20 EDT

AI's Expansion in Pharma and Biotech World

PANELISTS
Hongyue Dai
VP, Translational Bioinformatics, LifeMine Therapeutics

Panna Sharma
President & CEO
Lantern Pharma

ABOUT THE SPEAKERS

Hongyue Dai joined Cygnal Therapeutics in 2019. He formerly served as chief scientific officer (CSO) and chief bioinformatics officer (CBIO) at M2Gen, where he helped build the ORIEN, a cancer center network, to connect cancer hospitals with pharma companies for cancer research and drug development. While at M2Gen, Hongyue filed more than 10 patents on cancer prognosis models covering various cancer types. Hongyue also served as Executive Director of Informatics & Analysis in Discovery & Preclinical Sciences at Merck Research Labs. He managed genomics and genetics projects to support all therapeutic franchises for target identification, biomarker discovery, compound prioritization, and translating biomarkers in clinical trials. Prior to Merck, Hongyue was Research Associate Professor in the Physics Department at the University of Utah, where he analyzed and defended the highest energy cosmic ray particle, also known as the Oh-My-God or OMG particle. He then took on the role of Senior Data Analyst at Rosetta, where he co-developed the first microarray data error model to characterize the data uncertainty. He made significant contributions to the first FDA-approved multi-gene test kit for breast cancer prognosis, the MammaPrint. He also collaborated with Celera to develop the 14-gene test kit for ER-positive breast cancer patients. Hongyue received his undergraduate degree in nuclear physics from Peking University and his Ph.D. in astrophysics from the Institute of High Energy Physics of the Chinese Academy of Science.

Panna Sharma is the President and CEO of Lantern Pharma Inc. (LTRN), a clinical-stage biopharmaceutical company using its proprietary RADR® AI and machine learning platform to transform and improve the cost, pace, and timeline of oncology drug discovery and development. As CEO, he led Lantern through its IPO in 2020 by implementing strategic initiatives to leverage AI and genomics to develop Lantern's pipeline of precision oncology therapies and by working closely with venture investors to raise capital. Previously, Panna was President and CEO of Cancer Genetics, Inc (CGIX), and led them through their IPO in 2013. He started his career as an analyst and management consultant focused on healthcare and technology.

END OF PANEL DISCUSSION

Event Day

TRACK 1:
DIGITAL TRANSFORMATION

Now seen as a vital strategic step towards improved patient care, better transparency, cost-effectiveness, improved drug development efficiency and output quality, the moment has arrived for complete adoption of digital transformation across the pharma and biotech industry. This track discusses approaches in using information shared through industry-wide systems integration to predict consumer demand, link siloed information, and improve production and supply chain efficiency.

09:00 – 10:00 EDT

ROUNDTABLE 1:
Enabling your workforce: Necessary steps to equip teams to digitally transform the organization

- One step back, two steps forward: The importance of taking a step back to transform cultures and mindsets
- Scrutinize the efficiency of current processes and considering the commitment towards transformation
- People first, then tools: A look at the best technologies and approaches towards successfully executing a digital transformation strategy

Priya Bhambi
Global Head of Portfolio & Transformation
Takeda

11:10 – 12:10 EDT

SOLUTION FOCUS ROUNDTABLE 2:
Latest Trends and Innovations to Enable Digital Transformation of Biotech and Pharma R&D

- Speed-to-innovation has reached a fever pitch: What are R&D leaders around the world prioritizing to increase efficiency in drug and therapeutic development?
- Cloud computing and AI/ML functionality on the rise: How are organizations turning the theoretical into practical tools?
- Staying ahead of the game: How do we wrangle the explosion of data, and which technologies enable industry leaders to focus on cutting-edge science?

Garrick Myers
Head of Enterprise Customer Success
Benchling

Loren Perelman
Head of Enterprise Professional Services
Benchling

BENCHLING

Benchling

ABOUT THE SPEAKER

Garrick Myers is Benchling's Head of Enterprise Customer Success. He has spent his career in the life sciences designing, developing and deploying life sciences technology and business process solutions in support of clinical research - working both as SaaS provider and customer. Garrick has held a variety of positions throughout his career related to technology, data governance, quality, process development, inspection readiness, innovations and operational efficiency. Prior to joining Benchling, he served as Head of Clinical Technology Innovations at Vertex Pharmaceuticals. His education includes a Masters in Innovation and MBA from Northeastern University, and a B.S. in Biotechnology from James Madison University.

Loren Perelman is Benchling's Head of Enterprise Professional Services. His career has been focused on helping organizations make better use of their primary asset, data, by improving methods of collection and utilization. Prior to Benchling, Loren was VP of Scientific Solutions at Riffyn, working with various customers in the Biotech and Biopharma spaces. He has spent over a decade leading R&D, Process Development, and Manufacturing teams, with a focus on quality, analytical chemistry, and stats/modeling. He holds a PhD in Materials Science from UCSD and a B.S. in Chemistry from Harvey Mudd.

13:40 – 14:40 EDT

SOLUTION FOCUS ROUNDTABLE 3:
Digital Transformation in BioPharma Today and in the Future

Digital Transformation is one of the big trends in Life Sciences, recently accelerated by the pandemic. In this roundtable participants will discuss the areas where they have transformed their organization through digitalization and where they still see big potential. Share successes of digital transformation initiatives, hurdles encountered and how to overcome them as well the biggest learnings. Discuss how digitally transformed organizations might look like in the future and how it might change the industry.

- Understand which areas in BioPharma can benefit most from Digital Transformation
- Learn what typical hurdles for implementing Digital Transformation programs can be and how to overcome them
- Get inspired by the potential and future of Digital Transformation in BioPharma

John McCarthy
VP, Field Applications
BIOVIA, Dassault Systèmes

BIOVIA

Mitchell Winfree
Sales Leader
BIOVIA, Dassault Systèmes

15:50 – 16:50 EDT

ROUNDTABLE 4:
Transforming Drug Discovery Pipelines Through Innovative Leveraging of AI

- AI meets cheminformatics: from linear regression to deep learning
- Exploring successful scenarios for complex biological data integration in drug pipelines
- Extracting actionable insights from electronic health records and real world evidence data
- How has AI been applied to products and has there been a measurable impact?

Clément Chatelain
Head Human Genetics and Genomics Precision Medicine & Computational Biology, Sanofi

ABOUT THE SPEAKER

Clément Chatelain holds a PhD in Physics from the Ecole Normale Superieure in Paris. He conducted research at leading academic institutions including Massachusetts Institute of Technology, Cornell University, and INRIA (France) on various bioinformatic topics ranging from molecular modeling, systems biology, to disease modeling.Clement spent the last decade in the healthcare and pharmaceutical R&D industry. He has led translational projects in various therapeutic areas for new therapeutic target identification, biomarker discovery, and disease prioritization. He has a strong expertise in statistical genetics, systems biology, machine learning, and data lake infrastructures for omics data. He has been working with leading biobanks including UK Biobank and Finngen to mine real world evidence and genetic data to benefit therapeutic programs. At Sanofi he is currently leading statistical geneticists and data scientists to support precision medicine activities.

END OF TRACK 1

TRACK 2:
ANALYTICS & DATA VISUALISATION

The track will explore innovative approaches to process and generate value from large sums of data while also addressing techniques to translate into visual representations that serve to optimize decision-making and enhance operational efficiency throughout the drug product lifecycle.

09:00 – 10:00 EDT

ROUNDTABLE 1:
Networks and system biology for novel targets and biomarker identification in rare-diseases

- Challenges in understanding the networks of interactions and effects of those interactions on a global scale (rare-diseases vs common diseases)
- Case scenarios where biological networks (protein-protein, protein-gene interactions) have been instrumental for target or novel biomarker identification
- Learnings and complexities in the use network medicine (inc. RWE, biological networks, etc) for biomarker and target discovery
- Are clinical trials (Ph II and III) making use of data driven insights to define the clinical end points?

Piero Ricchiuto
Associate Director Bioinformatics, Computational Biology & Biomarker Discovery
Alexion, AstraZeneca Rare Disease Unit

ABOUT THE SPEAKER

Piero Ricchiuto holds a B.Sc, in Medical Biotechnology and M.Sc. in Bioinformatics obtained at the University of Milano-Bicocca (Italy). Piero was privileged to work among the best academic's labs around the world as Biotechnologist at San Raffaele Scientific Institute (Italy), PhD in Computational structural Biologist at the University of Leeds (UK) and a post-doc experience as Bioinformatician on -omics studies at Harvard Medical School of Boston (USA). Piero spent last decade working in the R&D pharmaceutical industry providing bioinformatics solutions for drug development and biomarker discovery, most recently as Associate Director of Bioinformatics and Data Science at Alexion Pharmaceutical, AstraZeneca Rare Unit. Piero's research spans from the application of docking solutions/simulations for protein folding and protein-protein interactions, multi-omics network-based analysis aimed to MoA of small molecules, to targeted and untargeted clinical proteomics for biomarker discovery.

11:10 – 12:10 EDT

SOLUTION FOCUS ROUNDTABLE 2:
Leveraging Data Analytics for the Lab and Beyond

The lab is producing a vast amount of data, information and knowledge. Organizations are increasingly applying advanced analytics to leverage this data. One of the keys for a meaningful analytics strategy is starting with the quality of data, beginning in the lab. In this roundtable, we will discuss areas of success applying advanced analytics and visualization, building models to both reduce physical experiments and to guide research, and how to ensure data quality and preserve the context from experiments in the lab.

- Discuss the sources for challenges in leveraging lab data today
- Understand the prerequisites for meaningful data re-use
- Learn how advanced data analytics tools can help you to improve lab productivity

Kai Zhang
Director, Product Marketing
BIOVIA, Dassault Systèmes

Luke Fisher
Global Leader, Biosciences Industry Process Consultants
BIOVIA, Dassault Systèmes

BIOVIA

ABOUT THE SPEAKERS

Kai Zhang's biography is not available

Luke Fisher is the Global Leader for the Bioscience Industry Process Consultants at BIOVIA / Dassault Systèmes. His background brings more than twenty years of experience in scientific informatics solutions. Luke has domain knowledge across the scientific informatics industry including past leadership positions at BIOVIA / Dassault Systèmes, ACD/Labs, CDD, Perkin Elmer and Dotmatics. He have supported a broad range of industries including the world's leading pharmaceutical, biotech, agricultural, chemicals, academic and government labs. Luke brings experience in scientific software solutions from the smaller scale deployment of point solutions (like molecular modeling packages) to the larger enterprise scale of ELNs, scientific workflow technologies, data content, analysis and visualization. In his current role, Luke and his group supports all global customers of laser focused on growth within the Design to Cure and Generative Therapeutics Design initiatives. He has a Ph.D. in computational chemistry from the University of Wisconsin Milwaukee.

15:50 – 16:50 EDT

ROUNDTABLE 4:
Assessing the best visualization and analytical tools to assist in making better informed decisions

- Roles of visualization in the Pharma/Biotech space
- Exploratory vs function-specific tools
- The Functional relationship of visualization to statistics and AI

Artur Veloso
Head of Bioinformatics
Repare Therapeutics

ABOUT THE SPEAKER

Artur Veloso trained as a bioinformatician at the University of Michigan, where he studied the dynamics of nascent RNA transcription. In 2014, he joined the Oncology Data Science group at the Novartis Institutes for BioMedical Research, where he supported pre-clinical and clinical immuno-oncology programs. In addition, he also spearheaded the characterization of the tumor microenvironment by applying deep learning approaches to digital pathology images. He joined Repare Therapeutics in 2018, an oncology drug discovery company focusing on identifying synthetic lethal partners through CRISPR screens. Currently, he heads the Bioinformatics team at Repare and is excited to have supported its growth from small biotech to two-compound clinical company. Although Artur trained as a data analyst, he is passionate about the development of bioinformatics tools to quickly bring solutions to biologists.

END OF TRACK 2

Event Day

TRACK 3:
ARTIFICIAL INTELLIGENCE / MACHINE LEARNING

Large quantities of biological and medical data brought by increased digitalization in industry goes hand in hand with next level machine cognition to aid efforts involving drug discovery & development, synthesis, drug repurposing, modeling & simulation, multi-parametric data analyses, clinical trials and beyond. This track explores verifiable use of advanced technologies to analyse data, unlocking scalable AI, leveraging AI to improve biological pathway fucnand more.

09:00 – 10:00 EDT

ROUNDTABLE 1:
Learnings from AI: Accelerating the Expansion of AI and Building Powerful AI Capabilities Internally

- Sharing the best practices: A roadmap for practical implementation and integration of AI
- How could AI help curate, manage, and analyse real-world data and translate them into actionable insights for predictive medicine?
- In an era of increased complexity, ensuring AI/ML is implemented in transparent, replicable, and ethical manner

John Chan
Head, ShinrAI Center for Artificial Intelligence/ Machine Learning
Takeda

ABOUT THE SPEAKER

John Chan is a technology executive, trained as a scientist and an engineer, with a 25-year career in data sciences. During this time, he built and led computational teams and pioneered innovation for global biopharma's and biotech start-ups. Most recently, he built a computer vision-based AI company, Syllable Life Sciences, and as its CEO, led its acquisition by Neumora. Prior to his CEO role John held several management roles in computational biology, bioinformatics and enterprise IT, including time as an Executive Director and Head of Informatics, Technology and Program Innovation at Novartis. John earned a Ph.D. in genetics and molecular biology from the University of Pennsylvania.

11:10 – 12:10 EDT

SOLUTION FOCUS ROUNDTABLE 2:
The Case for Scientific Portfolio Management

- Mechanism is king in drug development. Understanding the competition is queen
- At any given time, different users in the organization need different scientific insights
- What if there were one platform to satisfy everyone's needs and deliver multiple use cases?

CYTOREASON

Prof. Shai Shen-Orr
Co-founder and Chief Scientist
CytoReason

ABOUT THE SPEAKER

Professor Shai Shen-Orr is the Co-founder and Chief Scientist of CytoReason, a technology company developing computational disease models. He serves as Associate Professor in the Faculty of Medicine at the Technion—where he directs the laboratory of Systems Immunology and Precision Medicine. In his research, Prof. Shen-Orr develops new analytical methodologies for grappling with the intricate complexities of the immune system, especially as they occur in advanced age, and for defining biomarkers to evaluate immune health. His work has been featured and cited in numerous top-tier journals and systems biology textbooks, and has laid the foundation for CytoReason's disease models. To date, six of the world's top ten pharma companies use CytoReason's technology to speed up drug discovery and dramatically cut the cost of developing new medicines.

See next page for Track 3 continuation...

Event Day

13:40 – 14:40 EDT

SOLUTION FOCUS ROUNDTABLE 3: Applying AI and Machine Learning for Accelerated Drug Design

Expiring patents and unmet patients' needs demand faster and better innovation in Drug Discovery. An impactful method is the application of Artificial Intelligence (AI) and Machine Learning (ML). Organizations are leveraging internal and external data generated in the past and in the present for active learning. It allows to focus on the most promising targets and to reduce time-consuming and expensive physical testing. In the this round table we will discuss experiences leveraging AI and ML, benefits and hurdles and expectations how it will impact Drug Discovery in the future.

- **Learn how AI/ML can accelerate Drug Design**
- **Understand how Biopharma companies are using AI/ML today**
- **Discuss how AI/ML can improve your current approach to Drug Design**

Luke Fisher
Global Leader, Biosciences Industry Process Consultants
BIOVIA, Dassault Systèmes

David Crowley
Global Client Executive
BIOVIA, Dassault Systèmes

BIOVIA

ABOUT THE SPEAKERS

Luke Fisher is the Global Leader for the Bioscience Industry Process Consultants at BIOVIA / Dassault Systèmes. His background brings more than twenty years of experience in scientific informatics solutions. Luke has domain knowledge across the scientific informatics industry including past leadership positions at BIOVIA / Dassault Systèmes, ACD/Labs, CDD, Perkin Elmer and Dotmatics. He have supported a broad range of industries including the world's leading pharmaceutical, biotech, agricultural, chemicals, academic and government labs. Luke brings experience in scientific software solutions from the smaller scale deployment of point solutions (like molecular modeling packages) to the larger enterprise scale of ELNs, scientific workflow technologies, data content, analysis and visualization. In his current role, Luke and his group supports all global customers of laser focused on growth within the Design to Cure and Generative Therapeutics Design initiatives. He has a Ph.D. in computational chemistry from the University of Wisconsin Milwaukee.

Dave Crowley has worked with strategic accounts to help them deliver their industry leading and life changing offerings to their customers for 30 years. With a focus on biopharma industry for the last 23 years, Dave has engaged biopharma customers to exploit the value of Dassault Systèmes solutions that help them to transform their R&D and manufacturing businesses.

15:50 – 16:50 EDT

ROUNDTABLE 4: Furthering Organization-Wide Capabilities By Unlocking The Power of Scalable AI

- **Discussing how the evolving experiences brought by the global pandemic has transformed mindsets towards boosting digital investments and AI capabilities across the value chain**
- **Going beyond technologies and instilling the culture from the ground up**
- **Effective approaches in scaling AI/ML processes to improve research & preclinical stages and facilitate information transparency**

Panna Sharma
President & CEO
Lantern Pharma

ABOUT THE SPEAKER

Panna Sharma is the President and CEO of Lantern Pharma Inc. (LTRN), a clinical-stage biopharmaceutical company using its proprietary RADR® AI and machine learning platform to transform and improve the cost, pace, and timeline of oncology drug discovery and development. As CEO, he led Lantern through its IPO in 2020 by implementing strategic initiatives to leverage AI and genomics to develop Lantern's pipeline of precision oncology therapies and by working closely with venture investors to raise capital. Previously, Panna was President and CEO of Cancer Genetics, Inc (CGIX), and led them through their IPO in 2013. He started his career as an analyst and management consultant focused on healthcare and technology.

END OF TRACK 3

TRACK 4:
DATA MANAGEMENT / ARCHITECTURE

Data as a currency and its power to validate and ensure product viability is of increasing importance. Join these sessions to discuss strategies to collect, store, secure data and develop the framework for how the infrastructure will support your data strategy.

11:10 – 12:10 EDT

SOLUTION FOCUS ROUNDTABLE 2:
Addressing Data Residency, Analysis, and Growth Challenges with a Hyperscaler Mentality

With massive data growth and an expanding set of AI and Machine Learning applications, the competing demands for low-cost storage and high performance data access are a challenge to many biotech organizations. As you consider the storage needs of your own inhouse and co-located data centers, the world's largest hyperscalers have pioneered storage solutions to learn from. In this session, we'll discuss your own data management challenges as well as emerging storage architectures and pioneering new data management algorithms. How can we blur the lines between active and cold data and provide both easy accessibility and simpler cost models for ongoing use and long-term retention of valuable datasets? Join a roundtable with your peers to discuss how to:

- **Store more data, more cost-effectively, for the long term**
- **Overcome challenges in expanding the use of analytics, AI, and deep learning with richer, more expansive data sets**
- **Simply access archived data for model recalibration, additional analysis, and re-use**
- **Perform rich onsite analysis, bursting to the cloud only as necessary**
- **Meet data residency requirements**

Tim Sherbak
Product and Solutions Marketing
Quantum

QUANTUM

Quantum.

ABOUT THE SPEAKER

Tim Sherbak is an enterprise product and solutions marketing manager at Quantum, aligned to his passion for helping customers adopt new technologies and solutions for breakthrough results. Tim's unique perspectives emanate from a broad range of experiences in product development, marketing, and sales across a variety of storage, systems, software, datacenter, and cloud technologies. Tim holds an M.S. from the MIT Sloan School and a B.S. in Information Science from Syracuse University.

13:40 – 14:40 EDT

SOLUTION FOCUS ROUNDTABLE 3:
Sharing the Best Strategies to Secure Your Data With Microsoft Technologies

- **Demonstrating effective implementation of Microsoft Cloud to collaborate and share data while maintaining compliance and achieving the required security standard**
- **Discussing innovative approaches to boost employee productivity and reduce costs**
- **Addressing the challenges in creating alignment between the business and IT**

Nim Nadarajah
Partner, Advisory Services
CrucialLogics

Amol Joshi
Partner, Enterprise Solutions
CrucialLogics

CRUCIALLOGICS

CrucialLogics
consulting with a conscience

ABOUT THE SPEAKERS

Nim has more than 25 years of experience helping medical management professionals make better IT decisions. He has global expertise in the healthcare space, from the bedside of the patient to the manufacturing and distribution of compound drugs and medical equipment. Nim takes a consultative approach to problem-solving and a facilitative approach to leadership. A certified Project Manager by PMI (PMP), Nim has managed globally dispersed teams. He is a Microsoft Certified Expert with a BSc. in Geophysics and Psychology and an MBA in Technology Risk and Governance. He holds a Six Sigma Green Belt (SSGB), is a Certified Scrum Master (CSM), and is one of the most sociable and trusted IT leaders in the industry.

Amol Joshi's biography is not available

15:50 – 16:50 EDT

ROUNDTABLE 4:
Transforming biopharma R&D with Quantum Computing

- **The real value of quantum computing in drug research and development**
- **Current challenges for implementing quantum computing**
- **How could pharma accelerate its quantum computing journey?**
- **Real use cases/success stories**

Govinda Bhisetti
Principal Investigator and Head of Computational Chemistry
Biogen

ABOUT THE SPEAKER

Govinda Bhisetti is a Principal Investigator and Head of Computational Chemistry at Biogen. Previously, he worked at Vertex Pharmaceuticals for 22 years. He is a co-inventor of three FDA approved drugs: Agenerase, Lexiva and Incivek, a named inventor on 26 patents, and an author/co author of 75 research papers including review articles and book chapters. His current activities include building and application of advanced computational methods to discover novel drugs for CNS diseases. Govinda obtained his Ph.D. from Indian Institute of Science, Bangalore, India and worked as a post-doctoral fellow at Scripps Research Institute.

END OF TRACK 4

Event Day

TRACK 5:
OMICS-DRIVEN APPROACHES

The high-throughput and affordability of omics technologies has exponentially increased the volume of data available for the purposes such as target identification and better diagnosis and treatment in the clinic, among others. Join this track to gain insights into integrating omics and clinical data to aid precision medicine, addressing challenges associated in analyzing large scale omics data from multiple sources and more.

09:00 – 10:00 EDT

ROUNDTABLE 1:
A discussion on integrating multi-omics and clinical data to streamline precision medicine

- A look into how clinical multi-omics is progressing research and creating novel insights
- Exploring cases that have resulted in better diagnosis and treatment
- Extracting and demonstrating the value of multi-omics approaches in the clinic
- What does the future hold for omics-enabled precision medicine?

Hongyue Dai
VP, Translational Bioinformatics
LifeMine Therapeutics

ABOUT THE SPEAKER

Hongyue Dai joined Cygnal Therapeutics in 2019. He formerly served as chief scientific officer (CSO) and chief bioinformatics officer (CBIO) at M2Gen, where he helped build the ORIEN, a cancer center network, to connect cancer hospitals with pharma companies for cancer research and drug development. While at M2Gen, Hongyue filed more than 10 patents on cancer prognosis models covering various cancer types. Hongyue also served as Executive Director of Informatics & Analysis in Discovery & Preclinical Sciences at Merck Research Labs. He managed genomics and genetics projects to support all therapeutic franchises for target identification, biomarker discovery, compound prioritization, and translating biomarkers in clinical trials. Prior to Merck, Hongyue was Research Associate Professor in the Physics Department at the University of Utah, where he analyzed and defended the highest energy cosmic ray particle, also known as the Oh-My-God or OMG particle. He then took on the role of Senior Data Analyst at Rosetta, where he co-developed the first microarray data error model to characterize the data uncertainty. He made significant contributions to the first FDA-approved multi-gene test kit for breast cancer prognosis, the MammaPrint. He also collaborated with Celera to develop the 14-gene test kit for ER-positive breast cancer patients. Hongyue received his undergraduate degree in nuclear physics from Peking University and his Ph.D. in astrophysics from the Institute of High Energy Physics of the Chinese Academy of Science.

11:10 – 12:10 EDT

SOLUTION FOCUS ROUNDTABLE 2:
Turning Multi-omic Data Chaos into Translational Insights

- Exploratory Biomarkers: Myriad assays, lack of standardized nomenclature impede analysis
- Solving the Time-to-Analysis Bottleneck: Deeper connections, flexible data integration & QC
- Addressing Data Gaps On-Study: Strategies to create visibility, continuous data ingestion

QUARTZ BIO

Mike Waters
Vice President
QuartzBio, part of Precision for Medicine

ABOUT THE SPEAKER

Mike Waters collaborates with biopharmaceutical organizations to extract translational intelligence from the vast array of biomarker data collected across their drug development programs. Mike's rich industry experience spans specialty lab services, IVD, and scaling technology-based solutions to top-40 pharma to help sponsors maintain visibility into sample collection, processing, and consent status across broad portfolios of studies.

13:40 – 14:40 EDT

SOLUTION FOCUS ROUNDTABLE 3:
Integrating multi-tissue multi-omics data to gain insights into disease

- Data sets available for gain insights into disease
- Approach - Tools / pipelines for data mining, normalization challenges
- Data analysis and visualizations
- Meta-analysis and its challenges
- Actionable outcomes from the data analysis

EXCELRA

Chandra Sekhar Pedamallu
Associate Vice President - Bioinformatics
Excelra

ABOUT THE SPEAKER

Chandra Sekhar Pedamallu comes with extensive experience in Bioinformatics and Computational Biology specializing in cancer genomics. Before joining Excelra, Chandra was associated with Sanofi Inc., identifying novel drug targets in Oncology (Molecular and Immuno-oncology). Prior to Sanofi, he was at Dr. Meyerson Lab, Dana-Farber Cancer Institute, and a visiting scientist at The Broad Institute of MIT and Harvard. During his 6-year tenure at Harvard, he led microbial analysis, pathogen discovery projects in cancer and other diseases. He has contributed substantially to over a dozen projects under the auspices of the Cancer Genome Atlas (TCGA). Chandra holds a Ph.D. in Systems Engineering (area of research : Global Optimization) from School of Mechanical and Aerospace Engineering, Nanyang Technological University, Singapore. He has co-authored over 80 manuscripts, published in highly reputed journals including Nature, Nature Genetics, Science, Cell, PNAS, etc., and has been inducted as a Fellow of the Royal Society of Biology (FRSB).

15:50 – 16:50 EDT

ROUNDTABLE 4:
Addressing the challenges associated with large scale omics data analysis

- Exploring the common misconceptions and pitfalls in integrating large and high dimensional data sets
- Implementing statistical tools and ML
- Discussing strategies in translating outputs to be perceptible and easily visualized
- Explore successful case studies

Robert Van Den Berg
Senior Director, Head Data Science & Computational Vaccinology
GSK

ABOUT THE SPEAKER

Dr. Van den Berg heads the Data science and computational vaccinology group at GSK Vaccines' Rockville R&D center. In this role he and his team drive the application of data science to projects from discovery to life cycle management and from non-clinical to clinical questions. He joined GSK in 2010 and led various data and translational science projects. Before this, he worked as a postdoctoral researcher at the Katholieke Universiteit Leuven. He received a Ph.D. in Life Sciences from the Universiteit van Amsterdam on multivariate data analysis of high dimensional biological data.

END OF TRACK 5

Event Day

TRACK 6:
DATA INTEGRATION / BIG DATA

Through data-driven insights, healthcare has used data integration to promote value-based healthcare models. To improve medicine research and clinical trials, the pharmaceutical industry has used data integration across the value chain ecosystem, from discovery to commercialization. Integrating teams, concepts, and technology to develop an infrastructure capable of hosting big data and utilising it in a meaningful way will be the focus of this track.

09:00 – 10:00 EDT

ROUNDTABLE 1:
Building and Leveraging Big Data Assets to Drive Value End-to-End in the Pharmaceutical Pipeline

- What are the challenges to maximally leveraging big data to drive strategic decisions across functions?
  - Are data assets viewed as business assets by R&D leadership, and how is this evolving?
  - Discuss winning strategies for managing data as a multi-purpose asset
  - Assess barriers to collaboration throughout drug development that might be overcome by viewing bioinformatics and other data as a business asset

Gayle Wittenberg
VP Neuroscience Data Science and Digital Health
Janssen

ABOUT THE SPEAKER

Gayle Wittenberg is Head of Neuroscience Data Science and Digital Health at Janssen R&D, integrating DS/DH end-to-end along the pharmaceutical value chain. She holds a PhD in Neuroscience from Princeton and B.S in Physics and B.S. in Engineering Physics from Oregon State. She worked in Proteomics at BMS and led the Personalized Healthcare group at Siemens Corporate Research before joining Janssen in 2011 as Director of Integrative Solutions. Subsequently she held positions as Head of Translational Research and Precision Medicine Research IT (2016) and Head Intelligent Automation Pharm IT (2019). Her focus is bringing the right medicine to the right patient.

15:50 – 16:50 EDT

ROUNDTABLE 4:
Addressing The Challenge of Integration, Mining, and Analysis of Enterprise-Wide or Consortia-Level Datasets

- Building Trusted Research Environments (TREs) to integrate genotype and phenotype data with the ability to run user software easily
- Securely handling peta-byte scale data volumes
- Anonymising and linking sample IDs from a variety of healthcare, laboratory, database and other sources

David Sexton
Senior Director, VP, Digital Lab Systems
Harbinger Health

END OF TRACK 6

END OF Bioinformatics Strategy Meeting East Coast USA 2022
SEE YOU ON OUR NEXT EVENT!

PROVENTA TALENT
A PROVENTA INTERNATIONAL BRAND

Your Partner for Recruitment Solutions

We have the expertise to recruit across all markets within the life science industry and at global level.

VISIT OUR WEBSITE →

CONTACT US FOR MORE DETAILS

Michèle Bartouilh-Neugebauer
(Head of Talent Acquisition Division)

mbn@proventainternational.com

+44 (0)20 3314 0100 (UK)
+1 (617) 614 0377 (US)

www.proventaTALENT.com

Pharma FEATURES

Find your new partner,

explore our digital storefronts

www.pharmafeatures.com/supplier



Contact us to discuss how we can help generate growth for your business.

Jamie McBarek - Commercial Director
jmcbarek@proventainternational.com

+44 (0)20 3314 0100 (UK) | +1 (617) 614 0377 (US)
web@pharmafeatures.com

Venue

Le Meridien Hotel - Cambridge, Boston

Le Méridien Cambridge-MIT's elegant guest rooms and suites offer a place of luxurious sanctuary and unmatched comfort.

HOTEL DETAILS →

MAP & DIRECTIONS →

OUR FACE-TO-FACE MEETING IN MAY & JUNE 2022

Strategy Meeting Boston & San Francisco, USA and London, Europe

San Francisco - US West Coast

MAY 09 MON — DRUG DISCOVERY BIOLOGY
Drug Discovery Biology Strategy Meeting 2022
Westin St. Francis San Francisco on Union Square

MAY 10 TUE — MEDICINALCHEMISTRY
Medicinal Chemistry Strategy Meeting 2022
Westin St. Francis San Francisco on Union Square

MAY 11 WED — CLINICALOPERATIONS
Clinical Operations Strategy Meeting 2022
Westin St. Francis San Francisco on Union Square

MAY 11 WED — ONCOLOGY
Oncology Strategy Meeting 2022
Westin St. Francis San Francisco on Union Square

Boston/Cambridge MA - US East Coast

MAY 16 MON — PHARMACOVIGILANCE
Pharmacovigilance Strategy Meeting 2022
Le Meridien Cambridge

MAY 17 TUE — ONCOLOGY
Oncology Strategy Meeting 2022
Le Meridien Cambridge

MAY 18 WED — CLINICALOPERATIONS
Clinical Operations Strategy Meeting 2022
Le Meridien Cambridge

MAY 19 THUR — CLINICALTRIALSUPPLYCHAIN
Clinical Trial Supply Chain Strategy Meeting 2022
Le Meridien Cambridge

MAY 23 MON — BIOINFORMATICS
Bioinformatics Strategy Meeting 2022
Le Meridien Cambridge

MAY 24 TUE — DRUG DISCOVERY BIOLOGY
Drug Discovery Biology Strategy Meeting 2022
Le Meridien Cambridge

MAY 25 WED — MEDICINALCHEMISTRY
Medicinal Chemistry Strategy Meeting 2022
Le Meridien Cambridge

London - Europe

JUN 07 TUE — BIOINFORMATICS
Bioinformatics Strategy Meeting 2022
Radisson Blu Hotel London Stansted Airport

JUN 08 WED — DRUG DISCOVERY BIOLOGY
Drug Discovery Biology Strategy Meeting 2022
Radisson Blu Hotel London Stansted Airport

JUN 09 THUR — MEDICINALCHEMISTRY
Medicinal Chemistry Strategy Meeting 2022
Radisson Blu Hotel London Stansted Airport

JUN 14 TUE — ONCOLOGY
Oncology Strategy Meeting 2022
Radisson Blu Hotel London Stansted Airport

JUN 15 WED — CLINICALOPERATIONS
Clinical Operations Strategy Meeting 2022
Radisson Blu Hotel London Stansted Airport

JUN 16 THUR — PHARMACOVIGILANCE
Pharmacovigilance Strategy Meeting 2022
Radisson Blu Hotel London Stansted Airport

Accelerate Your Ability to Understand Methods for Data Mining → Storing → Integrating and Analysing Biological Data to Increase the Breadth of Drugs in R&D

Visit our website for future events →